What is Elasmogen?
Elasmogen is a specialized biopharmaceutical enterprise focused on the discovery and development of next-generation soloMER products. Founded in 2016, the company operates out of a high-growth biologics cluster in Scotland, utilizing its unique platform to engineer therapeutic proteins that offer superior tissue penetration and stability. The company's core focus lies in addressing complex pathologies, including solid-tumor oncology and inflammatory gut diseases, through highly targeted, potent, and well-tolerated biological agents. By maintaining a lean, research-intensive operational model, Elasmogen has successfully navigated the complexities of early-stage drug development, positioning itself as a high-value asset for potential pharmaceutical partnerships and long-term clinical success.
How much funding has Elasmogen raised?
Elasmogen has raised a total of $13.9M across 3 funding rounds:
Unspecified
$1.5M
Private Equity
$2.6M
Other Financing Round
$9.9M
Unspecified (2017): $1.5M with participation from Scottish Investment Bank and Deepbridge Capital
Private Equity (2020): $2.6M led by Deepbridge Capital
Other Financing Round (2022): $9.9M supported by BFG International
Key Investors in Elasmogen
Scottish Investment Bank
A national economic development agency of the Scottish Government that provides strategic financial support to foster innovation and economic growth within the region.
Deepbridge Capital
A private investor network specializing in life sciences and technology, providing capital and proactive management to highly-vetted, early-stage companies.
BFG International
A global manufacturing firm with a diverse portfolio, providing strategic backing to innovative companies through its investment arm.
What's next for Elasmogen?
With the successful closure of this major strategic investment, Elasmogen is poised to enter a pivotal phase of its corporate evolution. The primary objective for the upcoming fiscal periods involves the systematic advancement of its lead candidates through rigorous clinical trials and regulatory milestones. Strategic priorities include the optimization of manufacturing processes for its soloMER pipeline and the potential expansion of its research facilities to accommodate increased throughput in drug discovery. Furthermore, the company is expected to leverage its strengthened balance sheet to pursue collaborative opportunities with larger pharmaceutical entities, aiming to validate its platform's efficacy in broader patient populations. As the firm scales, the focus will remain on maintaining scientific excellence while navigating the path toward commercialization in the global oncology and immunology markets.
See full Elasmogen company page
